Wyeth

Pfizer Corporation

Merck Sharp + Dohme Corp.

Robert G K Donald

Annaliesa Sybil Anderson

Kathrin Ute Jansen

Mark Edward Ruppen

Justin Keith Moran

Michael James Flint

Maninder K Sidhu

Narender Kumar Kalyan

Jason Arnold Lotvin

Jianxin Gu

Avvari Krishna Prasad

Jin-Hwan Kim

Weiqiang Sun

Suddham Singh

Paul A Liberator

Srinivas Kodali

Rosalind Pan

Rajesh Kumar Kainthan

Amardeep Singh Bhupender Bhalla

Lakshmi Khandke

Wei Chen

Ingrid Lea Scully

Cindy Xudong Yang

Nishith Merchant

Ling Chu

Laurent Oliver Chorro

Scott Ellis Lomberk

Karen Kiyoko Takane

Evguenii Vinogradov

Xiaotian Zhong

Terri L Mininni

This invention provides a polypeptide derived fromor a fragment thereof, including compositions and methods thereof. In one embodiment, the compositions comprise a polypeptide derived fromor a fragment thereof, and modified O-polysaccharide molecules derived fromlipopolysaccharides or conjugates thereof. In a further aspect, the compositions further comprise modified O-polysaccharide molecules derived fromor conjugates thereof.

compositions and methods thereof

In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived fromlipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for differentserotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

In one aspect, the invention relates to an immunogenic composition that includes a mutanttoxin A and/or a mutanttoxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-typetoxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturingand in producingtoxins.

Compositions and methods relating to a mutanttoxin

In one aspect, the invention relates to an immunogenic composition that includes a mutanttoxin A and/or a mutanttoxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-typetoxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

Compositions relating to a mutant clostridium difficile toxin and methods thereof

In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

Compositions relating to a mutanttoxin and methods thereof

The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from, commonly referred to as group B(GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Group Bpolysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

Compositions and methods relating to a mutant clostridium difficile toxin

[object Object]

The invention relates to novel saccharides and uses thereof. In one aspect, the invention relates to a saccharide having a legionaminic acid moiety, a N-acetylgalactosamine moiety, a galactose moiety, and a glucose moiety. In another aspect, the invention relates to a saccharide having an altruronic acid moiety, a fucose moiety, and a glucose moiety. In yet another aspect, the invention relates to a saccharide having a repeating unit of a glycerol phosphate moiety and a glucose moiety, wherein the saccharide is from. In a further aspect, the invention relates to a saccharide having a repeating unit of -6-&#x3b2;-D-Fruf-2, wherein Fru is a fructose moiety, wherein the saccharide is from. In another aspect, the invention relates to an isolated antibody or fragment thereof that specifically binds to a saccharide described herein and uses thereof.

Saccharides and uses thereof

Growing community of inventors

South Orange, NJ, United States of America

Robert G K Donald